Recently, the Etoposide Injection submitted by Kindos Pharmaceutical Co., LTD., a subsidiary of King-Friend Co., LTD., has been approved for marketing by the US Food and Drug Administration (US FDA), and the commercial finished product has been dispatched to the US market. Kindos Pharmaceutical has become the first Chinese pharmaceutical enterprise to export this variety to the US market.
Etoposide Injection, when used in combination with other chemotherapy drugs, is indicated for first-line treatment of small cell lung cancer patients and refractory testicular tumors after standard treatment (including surgery, chemotherapy or radiotherapy).
Approval and immediate shipment is a significant demonstration of the quality of declaration, communication efficiency with the FDA, and marketing capabilities of international pharmaceutical enterprises. It also once again proves the outstanding comprehensive operational capabilities of Kindos Pharmaceutical, including international supply chain management. Kindos Pharmaceutical will continue to leverage the advantages of its high-standard quality system and integrated platform, continuously explore the potential for efficient operation, strengthen the synergy of the industrial chain, and work hand in hand with global partners to deliver high-quality Chinese answers to patients with major diseases.
